{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "DXCM",
  "name": "DexCom, Inc.",
  "url": "https://orbyd.app/dossiers/DXCM/",
  "json_url": "https://orbyd.app/dossiers/DXCM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is the binary; buying here chases extension into earnings risk.",
  "invalidation_trigger": "a daily close that breaches the risk threshold loses the recovery-base shelf and round number; secondarily, a Q2 miss or guide-down on the July 30 print, an Abbott Libre price/share headline, or the medtech-diagnostics theme flipping to SATURATED would confirm the break.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-22",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q3 2026 earnings date ~2026-10-29 is an aggregator estimate; Dexcom typically confirms the date about three weeks in advance.",
    "Recent insider sales run through pre-arranged Rule 10b5-1 plans (Foletta family trust plan adopted 2026-03-13), not discretionary decisions.",
    "DexCom has a history of outsized single-session post-earnings moves in both directions; gap risk around print dates is structural to the name.",
    "Levels cited use split/dividend-adjusted daily closes; unadjusted vendor quotes may show a different 52-week range."
  ],
  "body_markdown": "## Current Thesis\nThe July 30 print was the gate this coverage had flagged, and it cleared. Q2 revenue came in at $1.3084B against a $1.290B consensus, +13% reported and +12% organic; adjusted EPS $0.70 versus $0.61 expected. FY2026 revenue guidance moved to $5.180–5.250B from $5.160–5.250B, non-GAAP operating margin guidance to 23.5–24% from 23–23.5%, and non-GAAP gross margin guidance to roughly 64%. Ten sell-side target raises carry the date 7/31 — Mizuho, Piper Sandler and Stifel each to $95, Truist $93, RBC/Wells Fargo/BTIG/Canaccord-adjacent names at $90, Citi $88, and JP Morgan (Neutral) and Benchmark both at $82 — followed by Canaccord $90 on 8/3 and Argus $96 on 8/4. The pipeline's adjusted basis puts the last completed close at $84.75 (2026-08-07), 2.9% under the $87.31 52-week high, RSI(14) 65.1, +39.8% over three months. The mid-July structure — a recovery bounce still working a long-term moving average from below at a $76.65 close on 7/17 — has been replaced by a gap-driven advance in the top decile of its 52-week range. Life-cycle: **ACCELERATING**, dated by the 7/30 print and the 7/31–8/4 revision cluster. The qualifier is the calendar: no company-confirmed event falls between 2026-08-09 and 2026-09-08, and the next hard binary is the Q3 report expected around 2026-10-29.\n\n## Bull Case\n- **The guide moved up on both lines, 7/30.** FY26 revenue floor lifted to $5.180B from $5.160B (11–13% growth), non-GAAP operating margin to 23.5–24% from 23–23.5%. Margin was the raise the market had not been carrying.\n- **Gross margin expansion is measured, not promised.** Q2 non-GAAP gross margin 64.1% versus 60.1% a year earlier — 400bp — attributed on the call to manufacturing efficiencies and normalized shipping patterns. FY gross margin guidance moved to ~64%.\n- **International is outgrowing the base.** Q2 international revenue +19% reported / +16% organic against US +11%, on the 7/30 release. The geographic leg (G7 15 Day authorized by Health Canada 7/13/2026, 15.5-day wear, 8.0% MARD) is doing work independent of US payer dynamics.\n- **Capital return ran at scale into the drawdown.** $600M of stock repurchased during Q2 under a $1B FY2026 authorization, per the 7/30 release — two-thirds of the year's authorization spent in a single quarter that began with the stock in the $60s–$70s.\n- **The revision wave extended past the print week.** Canaccord to $90 (8/3) and Argus to $96 (8/4) landed three and four sessions after the cluster, so the bid was not confined to the 48-hour reaction window.\n- **Type 2 non-insulin remains the unpenetrated cohort.** CONNECT (reported 6/8/2026) showed G7 cutting A1C 1.6% over 26 weeks in Type 2 patients not on insulin; management framed coverage progress for that cohort as a 2026 priority on the 7/30 call.\n\n## Bear Case\n- **The raise was one-sided.** Only the bottom of the FY26 range moved ($5.160B → $5.180B); the $5.250B top was left untouched, and the range brackets the $5.224B consensus figure. A guide that lifts the floor and not the ceiling is a de-risking, not an acceleration.\n- **Two published targets sit under the tape.** JP Morgan (Neutral, $82) and Benchmark ($82), both dated 7/31, are below the 8/7 close of $84.75. The band from there to the highest print, Argus $96 (8/4), is where the whole reward argument lives.\n- **Supply into strength is documented.** A family trust tied to director Mark G. Foletta sold 2,000 shares at $80.00 on 7/31 and 2,000 shares at $85.32 on 8/3, per Form 4 — pre-arranged under a 10b5-1 plan adopted 3/13/2026, so not a discretionary view, but stock hitting the market at the highs all the same.\n- **An eleven-week hole in the calendar.** With ADA (6/5–8), CONNECT (6/8), the OTC pediatric / Stelo expansion (6/15) and the Q2 print all behind it, the name has no company-confirmed catalyst until the Q3 report around 10/29. Revision-driven legs decay when there is nothing new to revise against.\n- **Clinical data is not reimbursement.** The Type 2 non-insulin TAM converts only on payer coverage, which historically lags trial readouts by several quarters; no broad national coverage decision has been announced.\n- **The structural overhang did not go away.** Abbott's Libre pricing and share, pump-integration slots at Insulet and Tandem, and GLP-1 displacement (Lilly, Novo) remain the questions under the whole CGM complex, and none of them were settled by a single quarter's beat.\n\n## Setup & Price Structure\n- Last completed close $84.75 (2026-08-07); 52-week high $87.31; distance to high −2.9%; RSI(14) 65.1; three-month return +39.8%.\n- The 7/30 print produced the volume expansion the June advance lacked — that earlier leg ran near 0.74x average volume, which was the specific reason this note treated it as an unconfirmed bounce rather than a trend.\n- The pre-print congestion sits in the mid-to-high $70s: $77.98 close on 7/16 after the Mizuho/Truist raises, $76.65 on 7/17. The 7/30 gap left that shelf behind; a return into it would erase the earnings reaction entirely.\n- Crowding observables, stated as observables: twelve target changes inside five sessions (7/31–8/4); RSI(14) 65.1 with price within 3% of the 52-week high; retail-facing coverage clustering on the beat (multiple same-week \"jumps after earnings\" write-ups dated 8/1–8/2); insider stock sold into the move on 7/31 and 8/3 under a pre-existing plan. Cutting the other way: there is no earnings date inside 30 days, so the near-term event risk that normally accompanies this kind of extension is absent.\n- What would convert ACCELERATING to MATURING: the revision cluster completing with no follow-on datapoint — a named payer coverage decision, a product clearance, a competitive share disclosure — before the Q3 print.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-09 → 2026-09-08: no company-confirmed event.** The window is empty. Any move inside it is flow and sector beta, not company news.\n- **~2026-10-29 (est.)** — Q3 2026 earnings, after the close. Outside the 30-day window and the next hard binary; consensus EPS around $0.67 per aggregator listings. DexCom has historically confirmed the date roughly three weeks ahead.\n- **Undated, live** — payer coverage announcements for Type 2 non-insulin patients, and any Abbott disclosure on Libre pricing or share. Neither carries a scheduled date; both would re-price the name on the day they land.\n\n## What Would Change Our Mind\nThe structure that matters is the July 30 gap. Everything above the mid-$70s was created by one session's reaction to one quarter, and the pre-print range is still sitting directly underneath it. A daily close below $77 would close that gap and put price back inside the range it occupied when the setup was still a bounce contending with a long-term average from below — at which point the revision wave dated 7/31–8/4 becomes a sold-into event rather than the start of a leg. Two secondary conditions would compound it: the Q3 date passing around 10/29 without a second consecutive guidance raise (particularly a failure to move the $5.250B FY ceiling), and a named competitive or reimbursement headline — an Abbott Libre price action, or a payer declining Type 2 non-insulin coverage — that removes the datapoint the bull case is waiting on. A move to fresh 52-week highs above $87.31 on volume, by contrast, would argue the re-rating has further to run and that the $82 targets are the ones that get revised.\n\n## Correlation Notes\n- **Abbott (ABT)** is the direct read: Libre pricing and share commentary at ABT's quarterly prints moves the CGM complex on the same tape.\n- **Insulet (PODD), Tandem (TNDM)** — pump-integration partners whose sensor-partner disclosures cut both ways for DXCM's attach rate.\n- **Eli Lilly (LLY), Novo Nordisk (NVO)** — GLP-1 headlines are the structural swing factor the CGM complex has traded against since 2023; incretin news flow has repeatedly moved DXCM without any DXCM-specific news.\n- **Medtech beta (IHI, XLV)** — a high-multiple, mid-teens-growth medtech re-rating is rate- and risk-appetite-sensitive; the 39.8% three-month advance ran alongside a broadly bid market, which is not separable from company-specific alpha at this sample size.",
  "first_seen": "2026-06-09",
  "last_analyzed": "2026-08-09T19:49:34+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}